Europe Colorectal Cancer Diagnostics Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
1 –0 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
|
 CAGR |
% |
| Major Markets Players |
Europe Colorectal Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Stool examination, Imaging Test, Biopsy, Blood Test, Tumour markers, Others), Cancer Type (Adenocarcinoma, Colorectal Lymphoma, Gastrointestinal Stromal Tumors, Carcinoid Tumors, and Others), Cancer Stages (Stage 0, Stage I, Stage II, Stage III, Stage IV), Age Group (Geriatric, Adults, and Paediatric), End User (Hospital, Diagnostic Centers, Cancer Research Centers, Ambulatory Surgical Centers, Academic Institutes, and Others) - Industry Trends and Forecast to 2030.
Europe Colorectal Cancer Diagnostics Market Analysis and Size
Increasing awareness about colorectal cancer has enhanced the market demand. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved diagnostic processes and techniques also contributes to the rising demand for colorectal cancer diagnostics testing.
Data Bridge Market Research analyzes that the Europe colorectal cancer diagnostics market is expected to reach the value of USD 1,765.81 million by 2030, at a CAGR of 7.7% during the forecast period.
This market report also covers pricing analysis and technological advancements in depth.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
Product Type (Instruments, Consumables & Accessories), Test Type (Stool examination, Imaging Test, Biopsy, Blood Test, Tumour markers, Others), Cancer Type (Adenocarcinoma, Colorectal Lymphoma, Gastrointestinal Stromal Tumors, Carcinoid Tumors, and Others), Cancer Stages (Stage 0, Stage I, Stage II, Stage III, Stage IV), Age Group (Geriatric, Adults, and Paediatric), End User (Hospital, Diagnostic Centers, Cancer Research Centers, Ambulatory Surgical Centers, Academic Institutes, and Others) |
|
Countries Covered |
Germany, France, U.K, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland and Rest of Europe |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd., Abbott, Illumina, Inc. QIAGEN, Thermo Fisher Scientific Inc., QUEST DIAGNOSTICS INCORPORATED, Merck KGaA., Hologic, Inc., Siemens Healthcare GmbH, BD, Myriad Genetics, Inc., Koninklijke Philips N.V., PlexBio, FUJIFILM Corporation, CANON MEDICAL SYSTEMS CORPORATION., FONAR Corp., Medonica Co. LTD, MinFound Medical Systems Co., Ltd, Sternmed Gmbh, Bio-Rad Laboratories, Inc., Neusoft Corporation, BioFire Diagnostics, Agilent Technologies, Inc. and among others |
Market Definition
Colorectal cancer is a disease in which cells in the colon or rectum grow out of control. Sometimes it is called colon cancer for short. Depending on where they start, these cancers can also be called colon cancer or rectal cancer. Colon cancer and rectal cancer are often grouped because they have many features in common. The colon is the large intestine or large bowel. The rectum is the passageway that connects the colon to the anus.
Sometimes abnormal growths, called polyps, form in the colon or rectum. Over time, some polyps may turn into cancer. Screening tests can find polyps so they can be removed before becoming cancer. Screening also helps find colorectal cancer early, when the treatment works best.
Europe Colorectal Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing Prevalence of Colorectal Cancer
The big intestine is where colon cancer typically first manifests itself (colon). The digestive system ends with the colon. Colon cancer can strike anyone at any age, but it often strikes older persons. Small, benign (noncancerous) cell clusters called polyps commonly grow on the interior of the colon as the first signs of the condition. Some of these polyps may eventually develop into colon cancer.
People affected with colorectal cancer can see symptoms such as a persistent change in bowel habits, including diarrhea or constipation or a change in the consistency of the stool, rectal bleeding or blood in the stool, persistent abdominal discomfort, such as cramps, gas or pain, a feeling that the bowel doesn't empty completely, weakness or fatigue, unexplained weight loss.
- Rise in the Number of Patients Suffering from Diverticulitis and Ulcerative Colitis
Diverticulitis refers to inflammation of the diverticula, which are small pouches that form in the colon lining. Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) where people develop inflammation and ulcers in the lining of the large intestine. Treatment options include antibiotics, a temporary, clear liquid diet, pain relief medication, and surgery to remove part of the colon for a few cases only.
Opportunity
- Rise in Healthcare Expenditure for Cancer Diagnosis and Treatment
Across the globe, research and development activities are escalating owing to the public health expenditure with economic performances. Rising healthcare expenditure could result in better provision of research and development opportunities. Increasing the healthcare expenditure for cancer treatment also helps the patient take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their care), government expenditure, and various sources such as different healthcare schemes published by the government in different regions. It also includes health insurance and activities by non-governmental organizations. This increasing healthcare expenditure for cancer treatment is an opportunity for the market demand.
Restraint / Challenge
- Stringent Regulatory Policies
Regulation of drugs plays a significant role in healthcare. Achieving the requisite approval for legal selling medical devices or medications in such jurisdictions can entail substantial financial expenditure, which could take months or years to complete. If these constraints are not understood or taken into account, delays can seriously jeopardize the likelihood of success in a highly competitive market. The biologics such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, among others, are of significant importance for treating various diseases. However, their approval and marketing in multiple regions across the globe require a meeting of stringent regulatory standards and acceptance by various regulatory bodies.
Recent Developments
• In December 2022, Quest Diagnostics, the world's leading provider of diagnostic information services, and Northern Light Health, a large integrated healthcare system in Maine, announced a strategic laboratory collaboration designed to broaden access to innovative, quality, and cost-effective laboratory services powering affordable care for communities in Maine.
• In November 2022, Abbott was recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide. The CTA is the organization behind the Consumer Electronics Show (CES), the most influential technology event in the world.
Europe Colorectal Cancer Diagnostics Market Scope
Europe colorectal cancer diagnostics market is segmented into product type, test type, cancer type, cancer stages, age group, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables & Accessories
On the basis of product type, the Europe colorectal cancer diagnostics market is segmented into instruments, and consumables & accessories.
Test Type
- Stool Examination
- Imaging Test
- Tumor Markers
- Blood Test
- Biopsy
- Others
On the basis of test type, the Europe colorectal cancer diagnostics market is segmented into stool examination, imaging test, blood test, biopsy, tumor markers, and others.
Cancer Type
- Adenocarcinoma
- Colorectal Lymphoma
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Others
On the basis of cancer type, the Europe colorectal cancer diagnostics market is segmented into adenocarcinoma, colorectal lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others.
Cancer Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
On the basis of cancer stages, the Europe colorectal cancer diagnostics market is segmented into stage I, stage II, stage III, and stage IV.
Age Group
- Geriatric
- Adults
- Pediatric
On the basis of age group, the Europe colorectal cancer diagnostics market is segmented into geriatric, adults, and pediatric.
End User
- Hospitals
- Diagnostic Centers
- Cancer Research Centers
- Ambulatory Surgical Centers
- Academic Institutes
- Others
On the basis of end user, the Europe colorectal cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, ambulatory surgical centers, academic institutes, and others.
Europe Colorectal Cancer Diagnostics Market Regional Analysis/Insights
Europe colorectal cancer diagnostics market is segmented into product type, test type, cancer type, cancer stages, age group, and end user.
The countries covered in this market report are Germany, France, U.K, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland and Rest of Europe.
Germany is expected to dominate the market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the rising incidence and prevalence of colorectal nodules and cancer.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of regional brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Colorectal Cancer Diagnostics Market Share Analysis
The Europe colorectal cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Europe colorectal cancer diagnostics market.
Some of the major players operating in the Europe colorectal cancer diagnostics market are F. Hoffmann-La Roche Ltd., Abbott, Illumina, Inc. QIAGEN, Thermo Fisher Scientific Inc., QUEST DIAGNOSTICS INCORPORATED, Merck KGaA., Hologic, Inc., Siemens Healthcare GmbH, BD, Myriad Genetics, Inc., Koninklijke Philips N.V., PlexBio, FUJIFILM Corporation, CANON MEDICAL SYSTEMS CORPORATION., FONAR Corp., Medonica Co. LTD, MinFound Medical Systems Co., Ltd, Sternmed Gmbh, Bio-Rad Laboratories, Inc., Neusoft Corporation, BioFire Diagnostics, Agilent Technologies, Inc. and among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 INDUSTRY INSIGHTS:
6 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS
6.1 REGULATORY SCENARIO IN THE GERMANY
6.2 REGULATORY SCENARIO IN FRANCE
6.3 REGULATORY SCENARIO IN RUSSIA
6.4 REGULATORY SCENARIO IN ITALY
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER
7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS.
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATORY POLICIES
7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS.
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
8 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 PATHOLOGY-BASED INSTRUMENTS
8.2.1.1 PCR INSTRUMENTS
8.2.1.2 SLIDE STAINING SYSTEMS
8.2.1.3 TISSUE PROCESSING SYSTEMS
8.2.1.4 CELL PROCESSORS
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS
8.2.2 IMAGING INSTRUMENTS
8.2.2.1 ULTRASOUND SYSTEMS
8.2.2.2 CT SYSTEMS
8.2.2.3 MRI SYSTEMS
8.2.2.4 OTHERS
8.2.3 BIOPSY INSTRUMENTS
8.2.4 OTHERS
8.3 CONSUMABLES & ACCESSORIES
8.3.1 KITS
8.3.1.1 PCR KITS
8.3.1.2 DNA POLYMERASE KITS
8.3.1.3 NUCLEIC ACID ISOLATION KITS
8.3.1.4 OTHERS
8.3.2 REAGENTS
8.3.2.1 ASSAYS
8.3.2.2 BUFFERS
8.3.2.3 PRIMERS
8.3.2.4 OTHERS
8.3.3 OTHER CONSUMABLES
9 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 STOOL EXAMINATION
9.3 BLOOD TEST
9.3.1 COMPLETE BLOOD COUNT (CBC)
9.3.2 TUMOR MARKER TEST
9.3.3 LIVER ENZYME BLOOD TEST
9.4 IMAGING TEST
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.4.2 MRI
9.4.3 ULTRASOUND
9.4.4 POSITION EMISSION TOMOGRAPHY (PET)
9.4.5 OTHERS
9.5 TUMOR MARKERS
9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA)
9.5.2 CA19-9 BIOMARKER TEST
9.5.3 CA 50 MARKER TEST
9.5.4 OTHERS
9.6 BIOPSY
9.7 OTHERS
10 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES
10.1 OVERVIEW
10.2 STAGE III
10.3 STAGE IV
10.4 STAGE II
10.5 STAGE I
10.6 STAGE 0
11 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 GERIATRIC
11.3 ADULTS
11.4 PEDIATRIC
12 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
12.1 OVERVIEW
12.2 ADENOCARCINOMA
12.3 COLORECTAL LYMPHOMA
12.4 GASTROINTESTINAL STROMAL TUMORS
12.5 CARCINOID TUMORS
12.6 OTHERS
13 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 DIAGNOSTIC CENTERS
13.4 CANCER RESEARCH CENTERS
13.5 AMBULATORY SURGICAL CENTERS
13.6 ACADEMIC INSTITUTES
13.7 OTHERS
14 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY COUNTRY
14.1 EUROPE
14.1.1 GERMANY
14.1.2 FRANCE
14.1.3 U.K.
14.1.4 ITALY
14.1.5 SPAIN
14.1.6 RUSSIA
14.1.7 TURKEY
14.1.8 NETHERLANDS
14.1.9 BELGIUM
14.1.10 SWITZERLAND
14.1.11 REST OF EUROPE
15 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 F. HOFFMANN- LA ROCHE LTD
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 KONINKLIJKE PHILIPS N.V.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVELOPMENT
17.3 THERMO FISHER SCIENTIFIC INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.4 ILLUMINA, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.5 QUEST DIAGNOSTICS INCORPORATED
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 AGILENT TECHNOLOGIES, INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BD
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 BIOFIRE DIAGNOSTICS
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENT
17.1 BIO-RAD LABORATORIES, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 CANON MEDICAL SYSTEMS CORPORATION.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 FONAR CORP.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 FUJIFILM CORPORATION
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 GE HEALTHCARE.
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 HOLOGIC, INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 MEDONICA CO. LTD
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 MERCK KGAA
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 MINFOUND MEDICAL SYSTEMS CO., LTD
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENT
17.19 MYRIAD GENETICS, INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENT
17.2 NEUSOFT CORPORATION
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 PLEXBIO
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 QIAGEN
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENT
17.23 SIEMENS HEALTHCARE GMBH
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 STERNMED GMBH
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 10 EUROPE IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 12 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 13 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 14 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 15 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 16 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 17 GERMANY COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 18 GERMANY INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 19 GERMANY PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 20 GERMANY IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 21 GERMANY CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 22 GERMANY KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 23 GERMANY REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 24 GERMANY COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 25 GERMANY BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 26 GERMANY IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 27 GERMANY TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 28 GERMANY COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 29 GERMANY COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 30 GERMANY COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 31 GERMANY COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 32 FRANCE COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 33 FRANCE INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 34 FRANCE PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 35 FRANCE IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 36 FRANCE CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 37 FRANCE KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 FRANCE REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 FRANCE COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 40 FRANCE BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 41 FRANCE IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 42 FRANCE TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 43 FRANCE COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 44 FRANCE COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 45 FRANCE COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 46 FRANCE COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 47 U.K. COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 48 U.K. INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 U.K. PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 U.K. IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 U.K. CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 52 U.K. KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 U.K. REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 U.K. COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 U.K. BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 56 U.K. IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 57 U.K. TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 58 U.K. COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 59 U.K. COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 60 U.K. COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 61 U.K. COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 62 ITALY COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 63 ITALY INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 64 ITALY PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 65 ITALY IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 66 ITALY CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 67 ITALY KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 68 ITALY REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 69 ITALY COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 ITALY BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 71 ITALY IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 72 ITALY TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 ITALY COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 74 ITALY COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 75 ITALY COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 76 ITALY COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 77 SPAIN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 SPAIN INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 SPAIN PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 80 SPAIN IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 SPAIN CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 SPAIN KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 SPAIN REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 84 SPAIN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 SPAIN BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 86 SPAIN IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 SPAIN TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 88 SPAIN COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 89 SPAIN COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 90 SPAIN COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 91 SPAIN COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 RUSSIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 RUSSIA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 RUSSIA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 RUSSIA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 RUSSIA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 RUSSIA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 RUSSIA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 RUSSIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 100 RUSSIA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 101 RUSSIA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 102 RUSSIA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 103 RUSSIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 104 RUSSIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 105 RUSSIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 106 RUSSIA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 107 TURKEY COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 TURKEY INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 TURKEY PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 110 TURKEY IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 111 TURKEY CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 112 TURKEY KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 113 TURKEY REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 114 TURKEY COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 115 TURKEY BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 116 TURKEY IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 117 TURKEY TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 118 TURKEY COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 119 TURKEY COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 120 TURKEY COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 121 TURKEY COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 122 NETHERLANDS COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 NETHERLANDS INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 124 NETHERLANDS PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 NETHERLANDS IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 126 NETHERLANDS CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 127 NETHERLANDS KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 NETHERLANDS REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 129 NETHERLANDS COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 NETHERLANDS BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 131 NETHERLANDS IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 132 NETHERLANDS TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 133 NETHERLANDS COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 134 NETHERLANDS COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 135 NETHERLANDS COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 136 NETHERLANDS COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 137 BELGIUM COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 BELGIUM INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 BELGIUM PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 140 BELGIUM IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 BELGIUM CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 142 BELGIUM KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 143 BELGIUM REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 144 BELGIUM COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 BELGIUM BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 BELGIUM IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 147 BELGIUM TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 BELGIUM COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 149 BELGIUM COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 150 BELGIUM COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 151 BELGIUM COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 152 SWITZERLAND COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 153 SWITZERLAND INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 154 SWITZERLAND PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 155 SWITZERLAND IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 156 SWITZERLAND CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 157 SWITZERLAND KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 158 SWITZERLAND REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 159 SWITZERLAND COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 160 SWITZERLAND BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 161 SWITZERLAND IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 162 SWITZERLAND TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 SWITZERLAND COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 164 SWITZERLAND COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 165 SWITZERLAND COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 166 SWITZERLAND COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 167 REST OF EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT COLORECTAL CANCER IS EXPECTED TO DRIVE THE EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET
FIGURE 14 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 19 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 21 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 22 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022
FIGURE 23 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030)
FIGURE 25 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE
FIGURE 26 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 27 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 29 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 31 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 32 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 33 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 34 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 35 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 36 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 39 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 40 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 43 EUROPE COLORECTAL CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
